Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting

Area of Science:

• Cardiology
• Cardiac Surgery
• Pharmacology

Background:

• Catecholamines are standard for myocardial support during cardiopulmonary bypass (CPB) weaning.
• Limited data exists on levosimendan, a novel inotropic agent, in this context.
• This study evaluates levosimendan in patients with failure-to-wean from CPB post-coronary artery bypass grafting (CABG).

Purpose of the Study:

• To assess the efficacy of levosimendan in patients unable to wean from CPB post-CABG.
• To evaluate hemodynamic changes and weaning success with levosimendan.
• To compare levosimendan to conventional inotropic agents and intraaortic balloon pump (IABP) therapy.

Main Methods:

• Fifteen patients undergoing CABG received levosimendan (12-24 microg/kg loading dose, then 0.1-0.2 microg/kg/min infusion for 24h).
• Hemodynamic parameters were measured at baseline and 1, 24, and 48 hours postoperatively.
• Patients had failed conventional inotropic and IABP support.

Main Results:

• All patients demonstrated hemodynamic improvement with levosimendan.
• 93.3% of patients were successfully weaned from CPB.
• 53.3% experienced increased cardiac index and blood pressure, reducing catecholamine need.
• 33.3% of patients were lost postoperatively in the ICU.

Conclusions:

• Levosimendan is a potentially valuable agent for managing failure-to-wean from CPB after cardiotomy.
• It offers an alternative when conventional inotropic therapies are inadequate.
• Further research is warranted to optimize its use and understand outcomes.